

## FACSIMILE COVER SHEET

RECEIVED  
CENTRAL FAX CENTER

MAY 06 2004

OFFICIAL

**Licata & Tyrrell P.C.**66 E. Main Street  
Marlton, New Jersey

Tel: (856) 810-1515

Fax: (856) 810-1454

May 6, 2004

**TO:** Examiner Maher M. Haddad (TC1600)**GROUP:** 1644**FAX NUMBER:** 703-872-9307**ATTORNEY DOCKET NO.:** PENN-0749**SERIAL NO.:** 09/762,023**FILED:** June 28, 2001**NUMBER OF PAGES:** 18**MESSAGE:** Attached please find Amendment Transmittal Letter; Reply under 37 C.F.R.  
1.116 mailed February 6, 2004; and Certificate of Transmission by Facsimile.**Kathleen A. Tyrrell, Registration No. 38,350****URGENT! PLEASE DELIVER IMMEDIATELY UPON RECEIPT. THANK YOU!**


\* \* \* \* \*

If you have any questions, or did not receive the proper number of pages, or had trouble during  
transmission, please call 856-810-1515.**CONFIDENTIALITY NOTICE**

The information contained in this facsimile message is legally privileged and confidential, and intended only for the use of the individual(s) and/or entity(ies) named above. If you are not the intended recipient, you are hereby notified that any unauthorized disclosure, copying, distribution or taking of any action in reliance on the contents of the telecopied materials is strictly prohibited and review by any individual other than the intended recipient shall not constitute waiver of the attorney client privilege. If you have received this transmission in error, please immediately notify us by telephone in order to arrange for the return of the materials. Thank you.

<b>CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)</b> Applicant(s): Muzykantov et al.			Docket No. PENN-0749
Serial No. 09/762,023	Filing Date June 28, 2001	Examiner Haddad, Maher M.	Group Art Unit 1644
Invention: Targeting and Prolonging Association of Drugs to the Luminal Surface of the Pulmonary Vascular Endothelial Cells			
<p>I hereby certify that this _____ <u>Reply under 37 C.F.R. 1.116</u> _____ (Identify type of correspondence)</p> <p>is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. <u>703-872-9307</u>)</p> <p>on <u>May 6, 2004</u> (Date)</p> <p style="text-align: right;">_____ Kathleen A. Tyrrell (Typed or Printed Name of Person Signing Certificate)</p> <p style="text-align: right;">_____ <i>Kathleen A. Tyrrell</i> (Signature)</p> <p style="text-align: center;">Note: Each paper must have its own certificate of mailing.</p>			

P16/REV01

<b>AMENDMENT TRANSMITTAL LETTER (Small Entity)</b>				Docket No. <b>PENN-0749</b>	
Applicant(s): <b>Muzykantov et al</b>					
Serial No. <b>09/762,023</b>	Filing Date <b>June 28, 2001</b>	Examiner <b>Haddad, Maher M.</b>		Group Art Unit <b>1644</b>	
Invention: <b>Targeting and Prolonging Association of Drugs to the Luminal Surface of the Pulmonary Vascular Endothelial Cells</b>					
<u>TO THE COMMISSIONER FOR PATENTS:</u>					
Transmitted herewith is an amendment in the above-identified application.					
<input type="checkbox"/> Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted.					
<input type="checkbox"/> A verified statement to establish Small Entity status under 37 CFR 1.27 is enclosed.					
The fee has been calculated and is transmitted as shown below.					
<b>CLAIMS AS AMENDED</b>					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	2 -	20 =	0 x	\$9.00	\$0.00
INDEP. CLAIMS	2 -	3 =	0 x	\$43.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>					<b>\$0.00</b>
<input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. <b>50-1619</b> <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.					
 Signature <b>Kathleen A. Tyrrell, Reg. No. 38,350</b>			Dated: <b>May 6, 2004</b>		
<b>Licata &amp; Tyrrell P.C.</b> <b>66 East Main Street</b> <b>Marlton, New Jersey 08053</b> <b>Tel : 856-810-1515</b> <b>Fax: 856-810-1454</b>			I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.		
CC:			Signature of Person Mailing Correspondence		
			Typed or Printed Name of Person Mailing Correspondence		

**OFFICIAL**  
RESPONSE UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE  
EXAMINING GROUP 1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTER

MAY 06 2004

Attorney Docket No.: PENN-0749  
Inventors: Muzykantov et al.  
Serial No.: 09/762,023  
Filing Date: June 28, 2001  
Examiner: Haddad, Maher M.  
Group Art Unit: 1644  
Title: Targeting and Prolonging Association of  
Drugs to the Luminal Surface of the  
Pulmonary Vascular Endothelial Cells

## Certificate of Facsimile Transmission

I hereby certify that this document is being facsimile  
transmitted to the Patent and Trademark Office on  
the date shown below.

On May 6, 2004

  
Kathleen A. Tyrrell, Registration No. 38,350

Mail Stop  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sirs:

Reply under 37 C.F.R. § 1.116

This is a reply to the Final Rejection mailed February 6,  
2004, setting a three (3) month statutory period for response.  
Please enter the following amendments and remarks into the  
record.

Attorney Docket No.: PENN-0749  
Inventors: Muzykantov et al.  
Serial No.: 09/762,023  
Filing Date: June 28, 2001  
Page 2

Amendments to the claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks begin on page 4.